Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79

Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77

Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet (2011) 24.73

Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28

Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05

Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78

Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med (2010) 13.25

The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med (2009) 12.13

Translating the A1C assay into estimated average glucose values. Diabetes Care (2008) 11.55

Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66

Is there time for management of patients with chronic diseases in primary care? Ann Fam Med (2005) 10.12

Oxidative stress and diabetic complications. Circ Res (2010) 9.37

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology (2008) 8.65

Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk. The Diabetes Care From Diagnosis Research Team. BMJ (1998) 8.49

Complexity, leadership, and management in healthcare organisations. BMJ (2001) 8.06

Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet (2012) 6.81

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med (2005) 6.63

Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg (2003) 6.50

Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med (2004) 5.97

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med (2003) 5.87

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ (2011) 5.77

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 5.57

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ (2001) 5.55

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care (2008) 5.43

Diabetes control with reciprocal peer support versus nurse care management: a randomized trial. Ann Intern Med (2010) 5.18

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76

Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA (2011) 4.70

Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol (2006) 4.68

The barrier of hypoglycemia in diabetes. Diabetes (2008) 4.50

The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ (2007) 4.48

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33

Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment--Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial. BMJ (2010) 4.32

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol (2014) 4.30

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA (2014) 4.23

Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. Arch Intern Med (2011) 4.23

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet (2011) 4.15

Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14

The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care (2013) 4.08

Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A (2006) 4.07

Insulin resistance and cardiovascular disease. J Clin Invest (2000) 4.05

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia (2011) 3.97

Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93

Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77

Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care (2006) 3.67

Diabetes in older adults: a consensus report. J Am Geriatr Soc (2012) 3.63

Diabetes in older adults. Diabetes Care (2012) 3.62

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med (2008) 3.54

Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ (2001) 3.48

Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr (2009) 3.48

Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet (2008) 3.42

Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes (2012) 3.40

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ (2010) 3.26

Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care (2012) 3.24

Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg (2004) 3.23

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia (2010) 3.17

Cognitive dysfunction and diabetes mellitus. Endocr Rev (2008) 3.17

Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem (2005) 3.15

Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ (2001) 3.12

Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care (2010) 3.09

Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative. Diabetes Care (2002) 3.06

Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc (2001) 3.06

Hypoglycaemia in Type 2 diabetes. Diabet Med (2008) 3.00

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia (2009) 2.98

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care (2011) 2.96

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. BMJ (2000) 2.96

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet (2008) 2.96

Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A (2002) 2.96

Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95

Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med (2009) 2.89

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care (2012) 2.89

Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes (2015) 2.87

Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res (2010) 2.87

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care (2012) 2.84

Utility of the U.S. Preventive Services Task Force criteria for diabetes screening. Am J Prev Med (2013) 2.82

Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab (2012) 2.78

Competing demands or clinical inertia: the case of elevated glycosylated hemoglobin. Ann Fam Med (2007) 2.76

Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75

A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care (2008) 2.68

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66

Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J Res Med Sci (2012) 2.66

The treatment of type 2 diabetes. Dtsch Arztebl Int (2014) 2.66

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab (2013) 2.63

Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ (2008) 2.63

Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled trial. Am J Public Health (2011) 2.60

Point of care testing. BMJ (2001) 2.59

Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. CMAJ (2009) 2.58

Diabetic neuropathy: mechanisms to management. Pharmacol Ther (2008) 2.57